Abstract： Objective： To observe the clinical effect of Jiangzhi Tongluo Soft Capsules combined with western medicine on mixed hyperlipidemia with qi stagnation and blood stasis syndrome. Methods：A total of 62 cases of patients with mixed hyperlipidemia with qi stagnation and blood stasis syndrome were selected and divided into the Chinese patent medicine group and the control group according to the random number table method，with 31 cases in each group. The control group was treated with western medicine， and the Chinese patent medicine group was additionally treated with Jiangzhi Tongluo Soft Capsules based on the treatment of the control group. Both groups were treated for 8 weeks. The levels of blood lipid indexes [high-density lipoprotein cholesterol (HDL-C)，low-density lipoprotein cholesterol (LDL-C)，total cholesterol (TC)，and triglyceride (TG)]，hemorheology indexes (fibrinogen，plasma comparative viscosity， whole blood comparative viscosity，hematocrit，and whole blood reduction viscosity)，vascular endothelial function indexes [endothelin-1 (ET-1)，calcitonin gene-related peptide (CGRP)，and nitric oxide (NO)] and the incidence of adverse reactions before and after treatment，as well as the clinical effects were compared between the two groups. Results： After treatment， the total effective rate was 96.77% in the Chinese patent medicine group，higher than that of 74.19% in the control group (P＜0.05). The levels of TC，TG and LDL-C in the two groups were decreased when compared with those before treatment (P＜0.05)，and the levels of HDL-C were increased when compared with those before treatment (P＜0.05). The levels of TC， TG and LDL-C in the Chinese patent medicine group were lower than those in the control group (P＜0.05)， and the level of HDL-C was higher than that in the control group (P＜0.05). The levels of fibrinogen，plasma comparative viscosity，whole blood comparative viscosity，hematocrit and whole blood reduction viscosity in the two groups were decreased when compared with those before treatment (P＜0.05)，and the above five hemorheological indexes in the Chinese patent medicine group were lower than those in the control group (P＜0.05). The levels of ET-1 in the two groups were decreased when compared with those before treatment (P＜0.05)， and the levels of CGRP and NO were increased when compared with those before treatment (P＜0.05). The level of ET-1 in the Chinese patent medicine group was lower than that in the control group (P＜0.05)，and the levels of CGRP and NO were higher than those in the control group (P＜ 0.05). During the treatment，the incidence of adverse reactions was 6.45% in the Chinese patent medicine group and 12.90% in the control group， there being no significant difference (P＞0.05). Conclusion： Jiangzhi Tongluo Soft Capsules combined with western medicine for mixed hyperlipidemia with qi stagnation and blood stasis syndrome can enhance clinical effect，regulate blood lipid levels，and improve hemorheology and vascular endothelial function，with good safety.